The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US DOI Creative Commons

Aleksandar Ilic,

Maria J Tort, Alejandro Cané

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1279 - 1279

Published: Nov. 14, 2024

(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses administered during the year of life at 2, 4, 6 months, while booster dose is given 12 to 15 months. This study evaluated health economic effects PCV20 infant series within compared PCV15. (2) Methods: Using decision-analytic model, we calculated introducing PCV15 or five subsequent birth cohorts. Epidemiological data were drawn from peer-reviewed studies estimates vaccine effectiveness extrapolated established PCV13 PCV7 efficacy studies. Direct medical costs related disease treatment extracted literature inflated 2024 dollars. (3) Results: Over course years, implementation vaccination newborns United States, PCV15, projected prevent an additional 220 cases invasive disease, 6542 community-acquired pneumonia, 112,095 otitis media across strategy could 66 deaths linked these illnesses confer extra gains, amounting 5058 years 5037 quality-adjusted years. These prevented estimated save approximately USD 147 million over 5 (4) Conclusions: demonstrated that vaccinating with months would yield substantially greater return due serotypes covered by PCV20.

Language: Английский

Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines DOI Creative Commons
Laura King, Joseph A. Lewnard

Vaccine, Journal Year: 2024, Volume and Issue: 42(26), P. 126310 - 126310

Published: Sept. 10, 2024

Language: Английский

Citations

0
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US DOI Creative Commons

Aleksandar Ilic,

Maria J Tort, Alejandro Cané

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1279 - 1279

Published: Nov. 14, 2024

(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses administered during the year of life at 2, 4, 6 months, while booster dose is given 12 to 15 months. This study evaluated health economic effects PCV20 infant series within compared PCV15. (2) Methods: Using decision-analytic model, we calculated introducing PCV15 or five subsequent birth cohorts. Epidemiological data were drawn from peer-reviewed studies estimates vaccine effectiveness extrapolated established PCV13 PCV7 efficacy studies. Direct medical costs related disease treatment extracted literature inflated 2024 dollars. (3) Results: Over course years, implementation vaccination newborns United States, PCV15, projected prevent an additional 220 cases invasive disease, 6542 community-acquired pneumonia, 112,095 otitis media across strategy could 66 deaths linked these illnesses confer extra gains, amounting 5058 years 5037 quality-adjusted years. These prevented estimated save approximately USD 147 million over 5 (4) Conclusions: demonstrated that vaccinating with months would yield substantially greater return due serotypes covered by PCV20.

Language: Английский

Citations

0